Drugs / A/H7N9
A/H7N9
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03682120 | Nov 2018 → Apr 2020 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A/H7N9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03682120 ↗ |
| Known as | 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) | “3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22.” NCT03682120 ↗ |
| Known as | 2017 H7N9 IIV | “a pre-pandemic 2017 monovalent inactivated influenza A/H7N9 virus vaccine (2017 H7N9 IIV) manufactured by Seqirus Inc (Seqirus) administered at different dosages” NCT03682120 ↗ |
| Known as | pre-pandemic 2017 monovalent inactivated influenza A/H7N9 virus vaccine | “a pre-pandemic 2017 monovalent inactivated influenza A/H7N9 virus vaccine (2017 H7N9 IIV) manufactured by Seqirus Inc (Seqirus) administered at different dosages” NCT03682120 ↗ |
| Modality | Vaccine | “pre-pandemic 2017 monovalent inactivated influenza A/H7N9 virus vaccine” NCT03682120 ↗ |
| Route | Intramuscular | “3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22.” NCT03682120 ↗ |